AllSci News
Atea opens first dedicated antiviral program for hepatitis E with AT-587 Phase I trial
Atea Pharmaceuticals (Nasdaq: AVIR) has dosed the first participants in a Phase I clinical trial of AT-587, an oral nucleotide analog prodrug, for hepatitis...
ARPA-H awards USD 160m to accelerate rare disease gene editing through umbrella clinical trials
ARPA-H has announced up to USD 160 million in funding over five years for seven performer teams under its THRIVE (Treating Hereditary Rare Diseases with In...
FDA accelerates SOTIO’s CDH17-targeting colorectal cancer ADC with Fast Track designation
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group and headquartered in Prague with offices in Basel and Boston, announced that…
Sino Bio scores first BTD for an AT2R antagonist in China for neuropathic pain
Sino Biopharmaceutical Limited (HKEX: 01177) announced that TRD205, a peripherally-restricted, highly selective angiotensin II type 2 receptor (AT2R) antagonist developed by its…
Spero secures USD 105m non-dilutive financing backed by Utebzi royalties
Cambridge, Massachusetts-based Spero Therapeutics (Nasdaq: SPRO) announced a USD 105 million non-recourse, non-dilutive royalty financing with affiliates of...
HuyaBio's tucidinostat-nivolumab combo cuts melanoma progression risk by 58% in Phase III trial
HuyaBio International, which operates out of San Diego and Shanghai, China, has reported statistically significant Phase III results for HBI-8000...
Spero expands into autoimmune disease via USD 1.1b Innovent anti-CD40L deal
Spero Therapeutics in-licenses Innovent's Fc-silent anti-CD40L antibody in up to USD 1.1 billion deal, marking a full pivot from antibiotics to autoimmune
AstraZeneca pays USD 600m upfront to reacquire worldwide rights to former China R&D asset from Dizal
AstraZeneca has entered a global exclusive license agreement with China-based Dizal Pharmaceutical (SSE: 688192) for Zegfrovy (sunvozertinib), an oral...
Hansoh extends cross-border licensing strategy with Avere Nasdaq deal, highlighting evolution of biotech “NewCo” model
Private US-based Avere Therapeutics, Inc. has entered into a definitive all-stock merger agreement with NextCure, Inc. (Nasdaq: NXTC), a US-based...
ADDF and Michael J. Fox Foundation pool USD 5m to develop shared Alzheimer’s-Parkinson’s biomarkers
The Alzheimer’s Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced a USD 5 million research…
Alto Neuroscience raises USD 100m through stock offering as depression candidate enters Phase III
Mountain View, California-based Alto Neuroscience, Inc. (NYSE: ANRO) announced the pricing of an underwritten registered direct offering of common stock,...
US FDA approves Leqembi Iqlik for at-home subcutaneous initiation in early Alzheimer’s disease
The US FDA approved a supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as an initiation dose for early Alzheimer’s…
BMS seeking first FDA approval for molecular glue mezigdomide in heavily pretreated multiple myeloma
The US FDA has accepted for review a New Drug Application submitted by Bristol Myers Squibb (NYSE: BMY) for mezigdomide in combination with carfilzomib and...
Novartis signs up to access Chai Discovery’s AI antibody platform
San Francisco-based Chai Discovery announced a collaboration with Novartis under which the Swiss pharmaceutical company will gain access to Chai’s generative AI…
Voyager reports durable six-month preclin safety data for Alzheimer's gene therapy ahead of Phase I
Voyager Therapeutics (Nasdaq: VYGR) reported six-month preclinical toxicology data for VY1706 Alzheimer's gene therapy candidate at the Alzheimer's...
The AllSci Brief
Systematic R&D and deal news. Daily.